Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

07.03.2022 | review article

Update of the mechanism and characteristics of tuberculosis in chronic kidney disease

Review article

verfasst von: MD Xuehan Zhang, MD Pingshan Chen, PhD Gaosi Xu

Erschienen in: Wiener klinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The risk of tuberculosis (TB) is significantly increased in patients with chronic kidney disease (CKD), which is closely related to hyperparathyroidism, malnutrition and oxidative stress as well as immune deficiency in patients with end-stage renal disease (ESRD). Vitamin D deficiency and gender bias are independent risk factors. In the TB screening and diagnosis test of CKD, interferon-gamma release assays (IGRA), including T‑SPOT.TB test (T-SPOT) and QuantiFERON-TB Gold In-Tube (QFT-GIT) have been available. Many studies have found that they are more sensitive and specific than tuberculin skin test (TST). At present, IGRA has been used to study various types of immunocompromised patients. For CKD patients with TB, the choice and dosage of anti-TB drugs need to be reconsidered. Weekly treatment with rifapentin (RFT) and isoniazid (INH) for 3 months is an effective treatment for latent tuberculosis infection (LTBI) in hemodialysis (HD) patients. Therefore, in this review we discuss CKD and TB, its pathogenesis, clinical features, diagnosis and treatment advancements.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. PubMed Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. PubMed
3.
Zurück zum Zitat Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. Major infectious diseases. Washington (DC): 2017; 233–313 Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. Major infectious diseases. Washington (DC): 2017; 233–313
4.
Zurück zum Zitat Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90(1):34–40. PubMed Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90(1):34–40. PubMed
5.
Zurück zum Zitat Moran E, Baharani J, Dedicoat M, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. J Infect. 2018;77(4):291–5. PubMed Moran E, Baharani J, Dedicoat M, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. J Infect. 2018;77(4):291–5. PubMed
6.
Zurück zum Zitat Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial. 2003;16(1):38–44. PubMed Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial. 2003;16(1):38–44. PubMed
7.
Zurück zum Zitat Getahun H, Matteelli A, Abubakar I, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76. PubMedPubMedCentral Getahun H, Matteelli A, Abubakar I, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76. PubMedPubMedCentral
8.
Zurück zum Zitat Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52. PubMedPubMedCentral Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52. PubMedPubMedCentral
9.
Zurück zum Zitat Cahuayme-Zuniga LJ, Brust KB. Mycobacterial infections in patients with chronic kidney disease and kidney transplantation. Adv Chronic Kidney Dis. 2019;26(1):35–40. PubMed Cahuayme-Zuniga LJ, Brust KB. Mycobacterial infections in patients with chronic kidney disease and kidney transplantation. Adv Chronic Kidney Dis. 2019;26(1):35–40. PubMed
10.
Zurück zum Zitat Hussein M, Mooij J. Tuberculosis and chronic renal disease. Saudi J Kidney Dis Transpl. 2002;13(3):320–30. PubMed Hussein M, Mooij J. Tuberculosis and chronic renal disease. Saudi J Kidney Dis Transpl. 2002;13(3):320–30. PubMed
11.
Zurück zum Zitat Chavez K, Ravindran R, Dehnad A, Khan IH. Gender biased immune-biomarkers in active tuberculosis and correlation of their profiles to efficacy of therapy. Tuberculosis (Edinb). 2016;99:17–24. Chavez K, Ravindran R, Dehnad A, Khan IH. Gender biased immune-biomarkers in active tuberculosis and correlation of their profiles to efficacy of therapy. Tuberculosis (Edinb). 2016;99:17–24.
12.
Zurück zum Zitat Popova JA, Yadrihinskaya VN, Krylova MI, Sleptsovа SS, Borisovа NV. Comparison of clinical and laboratory parameters in patients with end-stage renal failure in the outcome of chronic glomerulonephritis and patients with end-stage renal failure in the outcome of other diseases. Wiad Lek. 2016;69(6):739–41. PubMed Popova JA, Yadrihinskaya VN, Krylova MI, Sleptsovа SS, Borisovа NV. Comparison of clinical and laboratory parameters in patients with end-stage renal failure in the outcome of chronic glomerulonephritis and patients with end-stage renal failure in the outcome of other diseases. Wiad Lek. 2016;69(6):739–41. PubMed
13.
Zurück zum Zitat Sathe KP, Mehta KP. Coexistence of atypical hemolytic uremic syndrome with membranoproliferative glomerulonephritis and antineutrophil cytoplasmic antibodies-associated vasculitis. Saudi J Kidney Dis Transpl. 2016;27(4):800–4. PubMed Sathe KP, Mehta KP. Coexistence of atypical hemolytic uremic syndrome with membranoproliferative glomerulonephritis and antineutrophil cytoplasmic antibodies-associated vasculitis. Saudi J Kidney Dis Transpl. 2016;27(4):800–4. PubMed
14.
Zurück zum Zitat Aibana O, Huang CC, Aboud S, et al. Vitamin D status and risk of incident tuberculosis disease: a nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Med. 2019;16(9):e1002907. PubMedPubMedCentral Aibana O, Huang CC, Aboud S, et al. Vitamin D status and risk of incident tuberculosis disease: a nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Med. 2019;16(9):e1002907. PubMedPubMedCentral
15.
Zurück zum Zitat Shu CC, Wei YF, Yeh YC, et al. The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship. Respir Res. 2020;21(1):51. PubMedPubMedCentral Shu CC, Wei YF, Yeh YC, et al. The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship. Respir Res. 2020;21(1):51. PubMedPubMedCentral
16.
Zurück zum Zitat Malik GH, Al-Mohaya SA, Al-Harbi AS, et al. Spectrum of tuberculosis in dialysis patients in saudi arabia. Saudi J Kidney Dis Transpl. 2003;14(2):145–52. PubMed Malik GH, Al-Mohaya SA, Al-Harbi AS, et al. Spectrum of tuberculosis in dialysis patients in saudi arabia. Saudi J Kidney Dis Transpl. 2003;14(2):145–52. PubMed
17.
Zurück zum Zitat Hauser AB, Stinghen AE, Kato S, et al. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int. 2008;28(3):S183–7. PubMed Hauser AB, Stinghen AE, Kato S, et al. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int. 2008;28(3):S183–7. PubMed
19.
Zurück zum Zitat Gibbons RA, Martinez OM, Garovoy MR. Altered monocyte function in uremia. Clin Immunol Immunopathol. 1990;56(1):66–80. PubMed Gibbons RA, Martinez OM, Garovoy MR. Altered monocyte function in uremia. Clin Immunol Immunopathol. 1990;56(1):66–80. PubMed
20.
Zurück zum Zitat D’Intini V, Bordoni V, Fortunato A, et al. Longitudinal study of apoptosis in chronic uremic patients. Semin Dial. 2003;16(6):467–73. PubMed D’Intini V, Bordoni V, Fortunato A, et al. Longitudinal study of apoptosis in chronic uremic patients. Semin Dial. 2003;16(6):467–73. PubMed
21.
Zurück zum Zitat Peraldi MN, Berrou J, Métivier F, Toubert A. Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis. Blood Purif. 2013;35(2):14–9. PubMed Peraldi MN, Berrou J, Métivier F, Toubert A. Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis. Blood Purif. 2013;35(2):14–9. PubMed
22.
Zurück zum Zitat Xiang FF, Zhu JM, Cao XS, et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016;38(1):7–14. PubMed Xiang FF, Zhu JM, Cao XS, et al. Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 2016;38(1):7–14. PubMed
23.
Zurück zum Zitat Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48(5):752–60. PubMed Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48(5):752–60. PubMed
24.
Zurück zum Zitat Morena M, Cristol JP, Senécal L, Leray-Moragues H, Krieter D, Canaud B. Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit. Kidney Int Suppl. 2002;80:109–14. Morena M, Cristol JP, Senécal L, Leray-Moragues H, Krieter D, Canaud B. Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit. Kidney Int Suppl. 2002;80:109–14.
25.
Zurück zum Zitat Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2431–8. PubMed Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2431–8. PubMed
26.
Zurück zum Zitat Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One. 2011;6(12):e29563. PubMedPubMedCentral Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One. 2011;6(12):e29563. PubMedPubMedCentral
27.
Zurück zum Zitat Chatenoud L, Jungers P, Descamps-Latscha B. Immunological considerations of the uremic and dialyzed patient. Kidney Int Suppl. 1994;44:S92–6. PubMed Chatenoud L, Jungers P, Descamps-Latscha B. Immunological considerations of the uremic and dialyzed patient. Kidney Int Suppl. 1994;44:S92–6. PubMed
28.
Zurück zum Zitat Cohen G. Immune dysfunction in uremia 2020. Toxins (Basel). 2020;12(7):439. Cohen G. Immune dysfunction in uremia 2020. Toxins (Basel). 2020;12(7):439.
29.
Zurück zum Zitat Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM. Tuberculosis in maintenance dialysis patients. Nephron. 2001;88(2):138–43. PubMed Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM. Tuberculosis in maintenance dialysis patients. Nephron. 2001;88(2):138–43. PubMed
31.
Zurück zum Zitat Soldati T, Neyrolles O. Mycobacteria and the intraphagosomal environment: take it with a pinch of salt(s). Traffic. 2012;13(8):1042–52. PubMed Soldati T, Neyrolles O. Mycobacteria and the intraphagosomal environment: take it with a pinch of salt(s). Traffic. 2012;13(8):1042–52. PubMed
32.
Zurück zum Zitat Cervantes JL, Oak E, Garcia J, et al. Vitamin D modulates human macrophage response to mycobacterium tuberculosis DNA. Tuberculosis (Edinb). 2019;116S:S131–S7. Cervantes JL, Oak E, Garcia J, et al. Vitamin D modulates human macrophage response to mycobacterium tuberculosis DNA. Tuberculosis (Edinb). 2019;116S:S131–S7.
33.
Zurück zum Zitat Ralph AP, Lucas RM, Norval M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis. 2013;13(1):77–88. PubMed Ralph AP, Lucas RM, Norval M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis. 2013;13(1):77–88. PubMed
34.
Zurück zum Zitat Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA. 1974;229(7):798–800. PubMed Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA. 1974;229(7):798–800. PubMed
35.
Zurück zum Zitat Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med. 1979;67(4):597–602. PubMed Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med. 1979;67(4):597–602. PubMed
36.
Zurück zum Zitat Sasaki S, Akiba T, Suenaga M, et al. Ten years’ survey of dialysis-associated tuberculosis. Nephron. 1979;24(3):141–5. PubMed Sasaki S, Akiba T, Suenaga M, et al. Ten years’ survey of dialysis-associated tuberculosis. Nephron. 1979;24(3):141–5. PubMed
37.
Zurück zum Zitat Malhotra KK, Dash SC, Dhawan IK, Bhuyan UN, Gupta A. Tuberculosis and renal transplantation—observations from an endemic area of tuberculosis. Postgrad Med J. 1986;62(727):359–62. PubMedPubMedCentral Malhotra KK, Dash SC, Dhawan IK, Bhuyan UN, Gupta A. Tuberculosis and renal transplantation—observations from an endemic area of tuberculosis. Postgrad Med J. 1986;62(727):359–62. PubMedPubMedCentral
38.
Zurück zum Zitat Belcon MC, Smith EK, Kahana LM, Shimizu AG. Tuberculosis in dialysis patients. Clin Nephrol. 1982;17:14–8. PubMed Belcon MC, Smith EK, Kahana LM, Shimizu AG. Tuberculosis in dialysis patients. Clin Nephrol. 1982;17:14–8. PubMed
39.
Zurück zum Zitat Leventhal Z, Gafter U, Zevin D, Turani H, Levi J. Tuberculosis in patients on hemodialysis. Isr J Med Sci. 1982;18(2):245–7. PubMed Leventhal Z, Gafter U, Zevin D, Turani H, Levi J. Tuberculosis in patients on hemodialysis. Isr J Med Sci. 1982;18(2):245–7. PubMed
40.
Zurück zum Zitat Cuss FM, Carmichael DJ, Linington A, Hulme B. Tuberculosis in renal failure: a high incidence in patients born in the third world. Clin Nephrol. 1986;25(3):129–33. PubMed Cuss FM, Carmichael DJ, Linington A, Hulme B. Tuberculosis in renal failure: a high incidence in patients born in the third world. Clin Nephrol. 1986;25(3):129–33. PubMed
41.
Zurück zum Zitat Mitwalli A. Tuberculosis in patients on maintenance dialysis. Am J Kidney Dis. 1991;18:579–82. PubMed Mitwalli A. Tuberculosis in patients on maintenance dialysis. Am J Kidney Dis. 1991;18:579–82. PubMed
42.
Zurück zum Zitat Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron. 1996;73(3):421–4. PubMed Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron. 1996;73(3):421–4. PubMed
43.
Zurück zum Zitat Oner-Eyüboglu AF, Akçay MS, Arslan H, Demirhan B, Kalpaklioglu AF. Extrapulmonary involvement of mycobacterial infections in dialysis patients. Transplant Proc. 1999;31(8):3199–201. PubMed Oner-Eyüboglu AF, Akçay MS, Arslan H, Demirhan B, Kalpaklioglu AF. Extrapulmonary involvement of mycobacterial infections in dialysis patients. Transplant Proc. 1999;31(8):3199–201. PubMed
44.
Zurück zum Zitat Sen N, Turunc T, Karatasli M, Sezer S, Demiroglu YZ, Oner Eyuboglu F. Tuberculosis in patients with end-stage renal disease undergoing dialysis in an endemic region of Turkey. Transplant Proc. 2008;40(1):81–4. PubMed Sen N, Turunc T, Karatasli M, Sezer S, Demiroglu YZ, Oner Eyuboglu F. Tuberculosis in patients with end-stage renal disease undergoing dialysis in an endemic region of Turkey. Transplant Proc. 2008;40(1):81–4. PubMed
45.
Zurück zum Zitat Vikrant S. Tuberculosis in dialysis: clinical spectrum and outcome from an endemic region. Hemodial Int. 2019;23(1):88–92. PubMed Vikrant S. Tuberculosis in dialysis: clinical spectrum and outcome from an endemic region. Hemodial Int. 2019;23(1):88–92. PubMed
46.
Zurück zum Zitat Vikrant S. Clinical profile of tuberculosis in patients with chronic kidney disease: a report from an endemic country. Saudi J Kidney Dis Transpl. 2019;30(2):470–7. PubMed Vikrant S. Clinical profile of tuberculosis in patients with chronic kidney disease: a report from an endemic country. Saudi J Kidney Dis Transpl. 2019;30(2):470–7. PubMed
47.
Zurück zum Zitat Abbara A, Davidson RN. Etiology and management of genitourinary tuberculosis. Nat Rev Urol. 2011;8(12):678–88. PubMed Abbara A, Davidson RN. Etiology and management of genitourinary tuberculosis. Nat Rev Urol. 2011;8(12):678–88. PubMed
48.
Zurück zum Zitat Abu-Zidan FM, Zayat I. Gallbladder tuberculosis (case report and review of the literature). Hepatogastroenterology. 1999;46(29):2804–6. PubMed Abu-Zidan FM, Zayat I. Gallbladder tuberculosis (case report and review of the literature). Hepatogastroenterology. 1999;46(29):2804–6. PubMed
49.
Zurück zum Zitat Goyal SC, Goyal R, Malhotra V, Kaushik K. Tuberculosis of the gallbladder. Indian J Gastroenterol. 1998;17(3):108. PubMed Goyal SC, Goyal R, Malhotra V, Kaushik K. Tuberculosis of the gallbladder. Indian J Gastroenterol. 1998;17(3):108. PubMed
50.
Zurück zum Zitat Wolde TG, Jiang K, Miao Y, Wei J. Gallbladder tuberculosis in a dialysis patient: a case-report. BMC Surg. 2020;20(1):67. PubMedPubMedCentral Wolde TG, Jiang K, Miao Y, Wei J. Gallbladder tuberculosis in a dialysis patient: a case-report. BMC Surg. 2020;20(1):67. PubMedPubMedCentral
51.
Zurück zum Zitat Lee IH, Kim SG, Kwon JG, et al. Intestinal tuberculosis in a patient with end-stage renal disease on hemodialysis: a case report. Medicine. 2020;99(32):e21641. PubMedPubMedCentral Lee IH, Kim SG, Kwon JG, et al. Intestinal tuberculosis in a patient with end-stage renal disease on hemodialysis: a case report. Medicine. 2020;99(32):e21641. PubMedPubMedCentral
52.
Zurück zum Zitat Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol. 2010;5(6):1114–22. PubMed Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol. 2010;5(6):1114–22. PubMed
53.
Zurück zum Zitat Pai M, Kunimoto D, Jamieson F, Menzies D. Diagnosis of latent tuberculosis infection. Can Respir J. 2013;20:23A–34A. Pai M, Kunimoto D, Jamieson F, Menzies D. Diagnosis of latent tuberculosis infection. Can Respir J. 2013;20:23A–34A.
54.
Zurück zum Zitat Shankar MS, Aravindan AN, Sohal PM, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant. 2005;20(12):2720–4. PubMed Shankar MS, Aravindan AN, Sohal PM, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant. 2005;20(12):2720–4. PubMed
55.
Zurück zum Zitat Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099–104. PubMed Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099–104. PubMed
57.
Zurück zum Zitat Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent mycobacterium tuberculosis infection. Centers for disease control and prevention. MMWR Recomm Rep. 2003;52(RR-2):15–8. PubMed Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent mycobacterium tuberculosis infection. Centers for disease control and prevention. MMWR Recomm Rep. 2003;52(RR-2):15–8. PubMed
58.
Zurück zum Zitat Lee SS, Chou KJ, Su IJ, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection. 2009;37(2):96–102. PubMed Lee SS, Chou KJ, Su IJ, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection. 2009;37(2):96–102. PubMed
59.
Zurück zum Zitat Grant J, Jastrzebski J, Johnston J, et al. Interferon-gamma release assays are a better tuberculosis screening test for hemodialysis patients: a study and review of the literature. Can J Infect Dis Med Microbiol. 2012;23(3):114–6. PubMedPubMedCentral Grant J, Jastrzebski J, Johnston J, et al. Interferon-gamma release assays are a better tuberculosis screening test for hemodialysis patients: a study and review of the literature. Can J Infect Dis Med Microbiol. 2012;23(3):114–6. PubMedPubMedCentral
60.
Zurück zum Zitat Redelman-Sidi G, Sepkowitz KA. IFN‑γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188(4):422–31. PubMed Redelman-Sidi G, Sepkowitz KA. IFN‑γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188(4):422–31. PubMed
61.
Zurück zum Zitat Ferguson TW, Tangri N, Macdonald K, et al. The diagnostic accuracy of tests for latent tuberculosis infection in hemodialysis patients: a systematic review and meta-analysis. Transplantation. 2015;99(5):1084–91. PubMed Ferguson TW, Tangri N, Macdonald K, et al. The diagnostic accuracy of tests for latent tuberculosis infection in hemodialysis patients: a systematic review and meta-analysis. Transplantation. 2015;99(5):1084–91. PubMed
62.
Zurück zum Zitat Bae W, Park KU, Song EY, et al. Comparison of the sensitivity of quantiFERON-TB gold in-tube and T‑SPOT.TB according to patient age. PLoS ONE. 2016;11(6):e156917. PubMedPubMedCentral Bae W, Park KU, Song EY, et al. Comparison of the sensitivity of quantiFERON-TB gold in-tube and T‑SPOT.TB according to patient age. PLoS ONE. 2016;11(6):e156917. PubMedPubMedCentral
63.
Zurück zum Zitat Du F, Xie L, Zhang Y, et al. Prospective comparison of QFT-GIT and T‑SPOT.TB assays for diagnosis of active tuberculosis. Sci Rep. 2018;8(1):5882. PubMedPubMedCentral Du F, Xie L, Zhang Y, et al. Prospective comparison of QFT-GIT and T‑SPOT.TB assays for diagnosis of active tuberculosis. Sci Rep. 2018;8(1):5882. PubMedPubMedCentral
64.
Zurück zum Zitat Wang H, Wang S, Xu L, Mao Y. The application of T.SPOT-TB assay for early diagnosis of active tuberculosis in chronic kidney disease patients receiving immunosuppressive treatment. J Invest Surg. 2020;33(9):853–8. PubMed Wang H, Wang S, Xu L, Mao Y. The application of T.SPOT-TB assay for early diagnosis of active tuberculosis in chronic kidney disease patients receiving immunosuppressive treatment. J Invest Surg. 2020;33(9):853–8. PubMed
65.
Zurück zum Zitat Seyhan EC, Sökücü S, Altin S, et al. Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transpl Infect Dis. 2010;12(2):98–105. PubMed Seyhan EC, Sökücü S, Altin S, et al. Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transpl Infect Dis. 2010;12(2):98–105. PubMed
66.
Zurück zum Zitat Hoffmann M, Tsinalis D, Vernazza P, Fierz W, Binet I. Assessment of an Interferon-gamma release assay for the diagnosis of latent tuberculosis infection in haemodialysis patient. Swiss Med Wkly. 2010;140(19–20):286–92. PubMed Hoffmann M, Tsinalis D, Vernazza P, Fierz W, Binet I. Assessment of an Interferon-gamma release assay for the diagnosis of latent tuberculosis infection in haemodialysis patient. Swiss Med Wkly. 2010;140(19–20):286–92. PubMed
67.
Zurück zum Zitat Sayarlioğlu H, Gül M, Eren Dağli C, et al. QuantiFERON-TB gold test for screening latent tuberculosis infection in hemodialysis patients. Tuberk Toraks. 2011;59(2):105–10. PubMed Sayarlioğlu H, Gül M, Eren Dağli C, et al. QuantiFERON-TB gold test for screening latent tuberculosis infection in hemodialysis patients. Tuberk Toraks. 2011;59(2):105–10. PubMed
68.
Zurück zum Zitat Kim SH, Lee SO, Park IA, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis. 2010;12(2):113–9. PubMed Kim SH, Lee SO, Park IA, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis. 2010;12(2):113–9. PubMed
69.
Zurück zum Zitat Ahmadinejad Z, Azmoudeh Ardalan F, Safy S, Nikbakht G. Diagnosis of latent tuberculosis infection in candidates for kidney transplantation (comparison of two tests). Acta Med Iran. 2012;50(5):305–10. PubMed Ahmadinejad Z, Azmoudeh Ardalan F, Safy S, Nikbakht G. Diagnosis of latent tuberculosis infection in candidates for kidney transplantation (comparison of two tests). Acta Med Iran. 2012;50(5):305–10. PubMed
70.
Zurück zum Zitat Al Jahdali H, Ahmed AE, Balkhy HH, et al. Comparison of the tuberculin skin test and Quanti-FERON-TB gold in-tube (QFT-G) test for the diagnosis of latent tuberculosis infection in dialysis patients. J Infect Public Health. 2013;6(3):166–72. PubMed Al Jahdali H, Ahmed AE, Balkhy HH, et al. Comparison of the tuberculin skin test and Quanti-FERON-TB gold in-tube (QFT-G) test for the diagnosis of latent tuberculosis infection in dialysis patients. J Infect Public Health. 2013;6(3):166–72. PubMed
71.
Zurück zum Zitat Agarwal SK, Singh UB, Zaidi SH, Gupta S, Pandey RM. Comparison of interferon gamma release assay & tuberculin skin tests for diagnosis of latent tuberculosis in patients on maintenance haemodialysis. Indian J Med Res. 2015;141(4):463–8. PubMedPubMedCentral Agarwal SK, Singh UB, Zaidi SH, Gupta S, Pandey RM. Comparison of interferon gamma release assay & tuberculin skin tests for diagnosis of latent tuberculosis in patients on maintenance haemodialysis. Indian J Med Res. 2015;141(4):463–8. PubMedPubMedCentral
72.
Zurück zum Zitat Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T‑SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol. 2007;2(1):68–73. PubMed Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T‑SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol. 2007;2(1):68–73. PubMed
73.
Zurück zum Zitat Soysal A, Toprak D, Koc M, Arikan H, Akoglu E, Bakir M. Diagnosing latent tuberculosis infection in haemodialysis patients: T‑cell based assay (T-SPOT.TB) or tuberculin skin test. Nephrol Dial Transplant. 2012;27(4):1645–50. PubMed Soysal A, Toprak D, Koc M, Arikan H, Akoglu E, Bakir M. Diagnosing latent tuberculosis infection in haemodialysis patients: T‑cell based assay (T-SPOT.TB) or tuberculin skin test. Nephrol Dial Transplant. 2012;27(4):1645–50. PubMed
74.
Zurück zum Zitat Chung WK, Zheng ZL, Sung JY, et al. Validity of interferon-γ-release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clin Microbiol Infect. 2010;16(7):960–5. PubMed Chung WK, Zheng ZL, Sung JY, et al. Validity of interferon-γ-release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clin Microbiol Infect. 2010;16(7):960–5. PubMed
75.
Zurück zum Zitat Kim SY, Jung GS, Kim SK, et al. Comparison of the tuberculin skin test and interferon‑γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection. 2013;41(1):103–10. PubMed Kim SY, Jung GS, Kim SK, et al. Comparison of the tuberculin skin test and interferon‑γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection. 2013;41(1):103–10. PubMed
76.
Zurück zum Zitat Aeddula NR, Pathireddy S, Thongprayoon C, Bathini T, Cheungpasitporn W. Contribution of T‑SPOT.TB assay to the diagnosis of active tuberculosis infection among chronic kidney disease patients on immunosuppressive therapy. J Invest Surg. 2020;33(9):859–60. PubMed Aeddula NR, Pathireddy S, Thongprayoon C, Bathini T, Cheungpasitporn W. Contribution of T‑SPOT.TB assay to the diagnosis of active tuberculosis infection among chronic kidney disease patients on immunosuppressive therapy. J Invest Surg. 2020;33(9):859–60. PubMed
77.
Zurück zum Zitat Christopoulos AI, Diamantopoulos AA, Dimopoulos PA, Goumenos DS, Barbalias GA. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol. 2009;10:36. PubMedPubMedCentral Christopoulos AI, Diamantopoulos AA, Dimopoulos PA, Goumenos DS, Barbalias GA. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol. 2009;10:36. PubMedPubMedCentral
78.
Zurück zum Zitat Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. PubMed Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. PubMed
79.
Zurück zum Zitat Sandul AL, Nwana N, Holcombe JM, et al. High rate of treatment completion in program settings with 12-dose weekly Isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93. PubMed Sandul AL, Nwana N, Holcombe JM, et al. High rate of treatment completion in program settings with 12-dose weekly Isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93. PubMed
80.
Zurück zum Zitat Lin SY, Chiu YW, Lu PL, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: high rates of adverse events. J Microbiol Immunol Infect. 2019;52(1):158–62. PubMed Lin SY, Chiu YW, Lu PL, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: high rates of adverse events. J Microbiol Immunol Infect. 2019;52(1):158–62. PubMed
81.
Zurück zum Zitat Vikrant S, Agarwal SK, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7(3–4):99–108. PubMed Vikrant S, Agarwal SK, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7(3–4):99–108. PubMed
82.
Zurück zum Zitat Nahid P, Dorman SE, Alipanah N, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of america clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95. PubMedPubMedCentral Nahid P, Dorman SE, Alipanah N, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of america clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95. PubMedPubMedCentral
83.
Zurück zum Zitat Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557–70. PubMed Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557–70. PubMed
Metadaten
Titel
Update of the mechanism and characteristics of tuberculosis in chronic kidney disease
Review article
verfasst von
MD Xuehan Zhang
MD Pingshan Chen
PhD Gaosi Xu
Publikationsdatum
07.03.2022
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-022-02009-y